CytoDyn (CYDY) Notes Payables (2013 - 2024)

CytoDyn (CYDY) posted Notes Payables of $3.5 million for Q1 2024, up 10484.85% on a QoQ basis from $33000.0 in Q4 2023.

CytoDyn (CYDY) Notes Payables (2013 - 2024) Analysis & Trends

CytoDyn's Notes Payables history runs 9 years deep, the most recent figure standing at $3.5 million for Q1 2024.

Quarterly Notes Payables changed N/A year-over-year to $3.5 million in Q1 2024, while the trailing twelve-month figure through Feb 2024 was $3.5 million (changed N/A YoY) and the FY2023 annual result came in at $79000.0, changed N/A from the prior year.
Notes Payables was $3.5 million for Q1 2024 at CytoDyn, up from $33000.0 in the prior quarter.
Across five years, Notes Payables topped out at $5.2 million in Q2 2020 and bottomed at $33000.0 in Q4 2023.
A 3-year average of $2.8 million and a median of $3.7 million in 2020 frame the typical range for Notes Payables.
Peak annual rise in Notes Payables reached 72.39% in 2020, while the deepest fall reached 45.01% in 2020.
CytoDyn's Notes Payables stood at $5.2 million in 2020, then sank by 99.37% to $33000.0 in 2023, then jumped by 10484.85% to $3.5 million in 2024.
Business Quant data shows CYDY's Notes Payables at $3.5 million in Q1 2024, $33000.0 in Q4 2023, and $4.4 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	CytoDyn	267.79 Mn	267.79 Mn	-

Download Data